We are live on ! Find out more
NCM

Nantahala Capital Management Portfolio holdings

AUM $2.72B
1-Year Est. Return 121.58%
This Fund
S&P 500
This Quarter Est. Return
+13.03%
1 Year Est. Return
+121.58%
3 Year Est. Return
+308.64%
5 Year Est. Return
+308.9%
10 Year Est. Return
+2,888.73%
AUM
$1.67B
AUM Growth
+$502M
Cap. Flow
+$375M
Cap. Flow %
22.44%
Top 10 Hldgs %
57.54%
Holding
148
New
14
Increased
40
Reduced
54
Closed
20

Top Buys

Rank Stock Value
1
SLNO
Soleno Therapeutics
SLNO
+$70.1M
2
EOLS icon
Evolus
EOLS
+$22.3M
3
RDNW
RideNow Group
RDNW
+$18M
4
ESTA icon
Establishment Labs
ESTA
+$17.1M
5
IWM icon
iShares Russell 2000 ETF
IWM
+$13.6M

Top Sells

Rank Stock Value
1
CASH icon
Pathward Financial
CASH
+$8.58M
2
RH icon
RH
RH
+$5.38M
3
VTYX
Ventyx Biosciences
VTYX
+$5.13M
4
IMTX icon
Immatics
IMTX
+$4.66M
5
MLKN icon
MillerKnoll
MLKN
+$4.42M

Sector Composition

Rank Sector Weight
1 Healthcare 35.39%
2 Consumer Discretionary 8.45%
3 Financials 4.4%
4 Communication Services 3.48%
5 Technology 2.68%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NVNO
76
enVVeno Medical
NVNO
$6.93M
$3.63M 0.22%
+20,181
New +$3.21M
ELUT icon
77
Elutia
ELUT
$35.7M
$3.56M 0.21%
1,650,000
– –
SRT
78
DELISTED
Startek Inc.
SRT
$3.47M 0.21%
+786,913
New +$3.32M
DNTH icon
79
Dianthus Therapeutics
DNTH
$6.21B
$3.42M 0.2%
328,433
-8,429
-3% -$93.1K
AYTU icon
80
AYTU BioPharma
AYTU
$26M
$3.09M 0.18%
1,086,812
– –
UNCY icon
81
Unicycive Therapeutics
UNCY
$138M
$2.98M 0.18%
343,818
-3,236
-0.9% -$21.2K
ABEO icon
82
CALL
Abeona Therapeutics
ABEO
$429M
$2.61M 0.16%
520,000
+468,000
+900% +$2.06M
GAIA icon
83
Gaia
GAIA
$32.9M
$2.47M 0.15%
915,029
+891,885
+3,854% +$2.4M
EHTH icon
84
CALL
eHealth
EHTH
$40M
$2.18M 0.13%
250,000
+46,900
+23% +$383K
LENZ
85
LENZ Therapeutics
LENZ
$168M
$2.15M 0.13%
+117,282
New +$1.94M
JBIO
86
Jade Biosciences
JBIO
$1.35B
$2.06M 0.12%
2,605
-109
-4% -$55.5K
MAX icon
87
MediaAlpha
MAX
$806M
$2.02M 0.12%
180,868
-53,504
-23% -$530K
NMTC icon
88
NeuroOne Medical Technologies
NMTC
$14.4M
$1.92M 0.11%
202,349
-5,984
-3% -$44.1K
PWP icon
89
Perella Weinberg Partners
PWP
$1.31B
$1.9M 0.11%
155,709
-102,564
-40% -$1.12M
JSPR icon
90
Jasper Therapeutics
JSPR
$30.5M
$1.76M 0.11%
222,827
-17,463
-7% -$117K
SSKN
91
DELISTED
Strata Skin Sciences
SSKN
$1.72M 0.1%
312,813
-13,682
-4% -$71.1K
IMTXW
92
DELISTED
Immatics N.V. Warrants
IMTXW
$1.63M 0.1%
558,977
– –
CONN
93
DELISTED
Conn's Inc.
CONN
$1.6M 0.1%
+359,371
New +$1.18M
RNAC icon
94
Cartesian Therapeutics
RNAC
$260M
$1.54M 0.09%
74,474
+1,141
+2% +$34.1K
RZLT icon
95
Rezolute
RZLT
$450M
$1.53M 0.09%
1,537,707
+768,101
+100% +$704K
SRL icon
96
Scully Royalty
SRL
$93.3M
$1.48M 0.09%
242,721
-55,770
-19% -$285K
NGNE icon
97
Neurogene
NGNE
$671M
$1.4M 0.08%
72,279
-2,721
-4% -$39K
QURE icon
98
CALL
uniQure
QURE
$3.14B
$1.35M 0.08%
200,000
+52,300
+35% +$346K
RILY icon
99
BRC Group Holdings
RILY
$299M
$1.31M 0.08%
62,520
– –
ZYXI
100
DELISTED
Zynex
ZYXI
$1.31M 0.08%
+120,000
New +$1.07M
2 3
4
5 6

Similar funds

TAM
Timucuan Asset Management Jacksonville, Florida $2.72B AUM 4.95% 1-Year Est. Return
XL
XN LP New York $2.72B AUM 46.67% 1-Year Est. Return
NB
Nicolet Bankshares Green Bay, Wisconsin $2.71B AUM 17.55% 1-Year Est. Return
PA
Profund Advisors Bethesda, Maryland $2.72B AUM 47.27% 1-Year Est. Return
BCM
Bowie Capital Management Richardson, Texas $2.71B AUM 5.42% 1-Year Est. Return
SCM
Shaolin Capital Management Miami, Florida $2.71B AUM 64.57% 1-Year Est. Return
HCM
Hollencrest Capital Management Newport Beach, California $2.7B AUM 23.62% 1-Year Est. Return
GC
Giverny Capital Montreal, Quebec, Canada $2.73B AUM 14.09% 1-Year Est. Return

Nantahala Capital Management's Q4 2023 Portfolio in Review

As of Q4 2023, Nantahala Capital Management held 148 positions worth $1.67B, up 43% from $1.17B the previous quarter. Its ten largest holdings account for 58% of the portfolio.

Nantahala Capital Management deployed $375M of net new capital in Q4 2023, opening 14 new positions and adding to 40 existing holdings. Its largest new stake was Abivax: 1,010,034 shares worth $10.8M.

By sector, the portfolio is most concentrated in Healthcare at 35% of assets, down from 36% a quarter earlier, followed by Consumer Discretionary and Financials.

On the sell side, the largest reduction was Pathward Financial, an estimated $8.58M trimmed.

  • Nantahala Capital Management's largest Q4 2023 buy was Abivax: 1,010,034 shares worth $10.8M.
  • Nantahala Capital Management added most to Soleno Therapeutics in Q4 2023, an estimated $70.1M increase.
  • Nantahala Capital Management's biggest Q4 2023 reduction was Pathward Financial, cutting an estimated $8.58M.
  • Nantahala Capital Management fully exited RH in Q4 2023, selling an estimated $5.38M.
  • Nantahala Capital Management's ten largest holdings make up 58% of its $1.67B portfolio in Q4 2023.
  • Nantahala Capital Management opened 14 new positions and closed 20 in Q4 2023.
  • Nantahala Capital Management's portfolio value rose 43% quarter-over-quarter to $1.67B.

Based on Nantahala Capital Management's 13F filing for Q4 2023, filed 14 Feb 2024.